The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.
Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagul
Johnson & Johnson’s Darzalex has acquired another indication after the FDA quickly approved it as part of a combination in newly-diagnosed multiple myeloma patients who are transplant i
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
